Table 3.
Multiple adjusted analysis of ASAS40 response in different BMI categories at 1 year of treatment with a first TNF inhibitor
| Model 1 | Model 2 | |||||
|---|---|---|---|---|---|---|
| Variable | OR | 95% CI | p | OR | 95% CI | p |
| Obese (ref: normal BMI) | 0.27 | 0.09–0.70 | 0.01 | 0.18 | 0.05–0.59 | 0.008 |
| Overweight (ref: normal BMI) | 0.62 | 0.24–1.14 | 0.13 | 0.66 | 0.34–1.30 | 0.23 |
| Age | 1.01 | 0.99–1.04 | 0.32 | 1.01 | 0.98–1.04 | 0.36 |
| HLA-B27 | 1.31 | 0.65–2.68 | 0.46 | 1.35 | 0.67–2.79 | 0.41 |
| Male sex | 2.41 | 1.28–4.66 | 0.007 | 2.57 | 1.35–5.01 | 0.005 |
| nr-axSpA (ref: AS) | 0.38 | 0.18–0.78 | 0.009 | 0.38 | 0.18–0.78 | 0.01 |
| Current smoking yes vs. no | 0.65 | 0.36–1.18 | 0.16 | 0.64 | 0.35–1.16 | 0.15 |
| Exercise (ref: no exercise) | 0.89 | 0.50–1.58 | 0.69 | 0.83 | 0.46–1.50 | 0.54 |
| BASDAI | 1.10 | 0.95–1.27 | 0.19 | 1.10 | 0.95–1.27 | 0.20 |
| BASMI | 0.76 | 0.63–0.90 | 0.002 | 0.75 | 0.63–0.89 | 0.002 |
| Elevated CRP | 1.69 | 0.94–3.08 | 0.08 | 1.65 | 0.91–3.03 | 0.10 |
| Enthesitis | 1.34 | 0.72; 2.52 | 0.36 | 1.29 | 0.69; 2.43 | 0.43 |
| DMARDs | 1.17 | 0.51; 2.71 | 0.71 | 1.14 | 0.48; 2.67 | 0.76 |
| NSAIDs | 1.21 | 0.39; 4.24 | 0.75 | 1.13 | 0.35; 4.07 | 0.84 |
| Infliximab (ref: other TNFi) | 0.66 | 0.26–1.65 | 0.37 | |||
| Obese with infliximab (ref: other TNFi) | 3.55 | 0.41–30.1 | 0.24 | |||
| Overweight with infliximab (ref: other TNFi) | 0.73 | 0.15–3.26 | 0.68 | |||
Analysis performed in 259 patients
AS Ankylosing Spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASMI Bath Ankylosing Spondylitis Mobility Index, BMI body mass index, CI confidence interval, CRP C-reactive peptide, DMARDs disease-modifying antirheumatic drugs, HLA-B27 human leucocyte antigen-B27, nr-axSpA nonradiographic axial spondyloarthritis. NSAIDs nonsteroidal anti-inflammatory drugs, OR odds ratio, ref reference, TNFi tumor necrosis factor inhibitor